{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/181442444"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Prexa Pharmaceuticals is developing a pipeline of early stage products with primary action on the neurotransmitter dopamine, potentially providing new alternatives to treating CNS diseases and disorders such as ADHD, depression and Parkinson's disease." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "biospace.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/7782209"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/181442444" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/454778640"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/181442444"] } } }
